marketcaparena

Mesoblast Ltd

MESO

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

mesoblast.com ↗

Leadership

  • James Michael ObrienChief Financial Officer
  • Silviu ItescuChief Executive Officer and Managing Director
  • Eric Allen RoseChief Medical Officer,Director
Employees
81
Business address
MELBOURNE, VICTORIA, C3
Fiscal year ends
June 30
Listed
Nasdaq · MESO

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$14.50
−$1.36 (−8.58%)past year
Market cap
$1.88B
At close
Sep 28, 2026

Share price vs index

Mesoblast's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Mesoblast is ahead, orange while it is behind. The values at the end are each one's change over the range.

Income statement

Revenue, gross profit and net income

FY26
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

FY26
Full year
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalAddedSubtracted

Operating leverage

FY26
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY26
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY26
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY26
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Balance sheet

Assets, liabilities and equity

Q4 26
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

War chest

Q4 26
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.